To: All
VIMRX Launches New Web Site
www.vimrx.com Offers Easy Navigation to Company Information, News and Investor
Relations Information
WILMINGTON, DE--(BW HealthWire)--August 3, 1998--
VIMRX Pharmaceuticals Inc. (Nasdaq: VMRX - news) launched a new and improved company web site today --
www.vimrx.com -- which offers investors, researchers, medical practitioners and other interested parties easy navigation of
current company background, financial reports, news and information on VIMRX and its subsidiaries: Nexell Therapeutics
Inc., Innovir Laboratories, Inc. and, upon completion, Ventiv BioGroup Inc.
''Our prime directive when redesigning our web site was to offer easy to use, timely and accurate information on our
company and individual subsidiaries,'' stated Richard L. Dunning, president and CEO, VIMRX.
VIMRX's Internet site utilizes frames and JAVA technology to be more interactive, user friendly, and very easy to navigate.
The web site includes VIMRX At A Glance, Subsidiary Overviews, News, Investor Relations, Financial Reports, Executive
Profiles, Job Opportunities and a Portfolio Overview. The company is working on a 'FAQ - Frequently Asked Questions'
section and plans to add this to the site in the near future.
The new VIMRX web site was designed and built internally by Robert J. Meister, VIMRX System Administrator.
VIMRX Pharmaceuticals Inc.
VIMRX Pharmaceuticals Inc. (NASDAQ: VMRX - news) is a biotechnology company developing innovative technologies
to improve human health. VIMRX's portfolio will include three majority owned subsidiaries: Nexell Therapeutics Inc., a
company formed with Baxter Healthcare Corporation focused on cell therapeutics for cancer and other life threatening
diseases; Innovir Laboratories, Inc. (NASDAQ: INVR - news), which develops oligozymes for use as both therapeutics and
as pharmaceutical research tools; and, upon completion, Ventiv BioGroup, a biotechnology development company formed
with Columbia University focused on research and development programs in the areas of cancer, diabetes, cardiovascular
disease, wound healing and skin diseases.
The Private Securities Litigation Reform Act of 1995 provides a ''safe harbor'' for certain forward-looking statements. The
forward- looking statements contained in this release are subject to certain risks and uncertainties. Actual results could differ
materially from current expectations. Among the factors which could affect the Company's actual results and could cause
results to differ from those contained in the forward-looking statements contained herein are: the timely commencement and
success of the Company's clinical trials and other research endeavors, delays in receiving FDA or other regulatory
approvals, the development of competing therapies and/or technologies, the terms of any future strategic alliances, the
possible need for additional capital, and any additional factors described from time to time in the Company's periodic reports
on Form 10-K and 10-Q, and any prospectus describing the Company's securities.
NOTE TO INVESTORS AND EDITORS: VIMRX's press releases are available on the Internet through www.vimrx.com
and through BusinessWire's web site at businesswire.com. The releases are also available at no charge through
BusinessWire's fax-on-demand service at 800-411-8792.
Contact:
Media Contact: Laura A. Mastrangelo
VIMRX Pharmaceuticals
302-998-1734
or
Investor Contact: Dian Griesel, Ph.D.
The Investor Relations Group
212-664-8489 |
